Literature DB >> 27766397

Risk Factors for Cholangiocarcinoma After Initial Hepatectomy for Intrahepatic Stones.

Ze-Wu Meng1, Sheng-Hua Han1, Jin-Hai Zhu1, Liang-Yi Zhou1, Yan-Ling Chen2.   

Abstract

BACKGROUND: Aggressive hepatectomy is effective in treating intrahepatic stones and may minimize the deleterious consequences of subsequent cholangiocarcinoma (S-CCA). The risk factors of S-CCA after different methods of hepatectomy may vary with the resection scope of stone-affected segments.
METHODS: We reviewed the records of 981 patients of primary intrahepatic stones with elective hepatectomy from January 2000 to December 2010. The clinical characteristics of patients in the S-CCA group (n = 55) and the control group (n = 926) were compared. The uniformity between extent of liver resection (ELR) with stone-affected segments (SAS) was segmented into 2 varieties: ELR = SAS with ELR < SAS according to the different hepatic resection scopes. Cox regression model with forward selection was used to identify the risk factors of S-CCA.
RESULTS: In the univariate analysis, significant differences were observed between the S-CCA and control groups concerning stone location (unilateral 43.6 and 65.2 %, bilateral 56.4 and 34.8 %), residual stones (32.7 and 11.6 %), hepaticojejunostomy (43.6 and 30.9 %), and uniformity between ELR with SAS (ELR = SAS 20.0 and 42.6 %, ELR < SAS 80.0 and 57.4 %). Residual stones [hazard ratio (HR) 2.101, P = 0.016], hepaticojejunostomy (HR 1.837, P = 0.026) and uniformity between ELR and SAS (HR 2.442, P = 0.013) were independent prognostic factors for S-CCA by a Cox regression analysis with forward selection. In the subsection of ELR = SAS group, the 5- and 10-year postoperative tumor occurrence rates of unilateral and bilateral stones group were 0.9 versus 1.9 % and 3.0 versus 4.1 %, respectively (P = 0.663, log-rank). In the other subsection of ELR < SAS group, the 5- and 10-year postoperative tumor occurrence rates of unilateral and bilateral stones group were 3.4 versus 3.9 % and 6.8 versus 13.2 %, respectively (P = 0.047, log-rank), and the 5- and 10-year postoperative tumor occurrence rates of residual stones and non-residual stones group were 5.8 versus 3.0 % and 16.0 versus 7.9 %, respectively (P = 0.015, log-rank).
CONCLUSIONS: Patients who underwent aggressive hepatectomy and had ELR = SAS had better outcomes than those with ELR < SAS. In the patients with ELR = SAS, the S-CCA rates of unilateral and bilateral stones were low and comparable. However, patients with ELR < SAS and bilateral intrahepatic or residual stones should be monitored more carefully for high-risk factors of S-CCA.

Entities:  

Mesh:

Year:  2017        PMID: 27766397     DOI: 10.1007/s00268-016-3752-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study.

Authors:  Zhen-Yu Liu; Yan-Ming Zhou; Le-Hua Shi; Zheng-Feng Yin
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2011-12

2.  Outcomes of hepatectomy for hepatolithiasis.

Authors:  Tung-Yen Lee; Yao-Li Chen; Hung-Chi Chang; Chien-Pin Chan; Shou-Jen Kuo
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

3.  Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.

Authors:  Y-T Kim; J S Byun; J Kim; Y H Jang; W J Lee; J K Ryu; S W Kim; Y B Yoon; C Y Kim
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb

4.  Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma.

Authors:  M F Chen; Y Y Jan; T L Hwang; L B Jeng; T S Yeh
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

5.  Hepatic resection for bilateral hepatolithiasis: a 20-year experience.

Authors:  Chia-Cheng Lin; Ping-Yi Lin; Chih-Jan Ko; Yao-Li Chen; Shou-Tung Chen; Shou-Jen Kuo
Journal:  ANZ J Surg       Date:  2012-09-26       Impact factor: 1.872

6.  Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis.

Authors:  T Ohta; T Nagakawa; N Ueda; T Nakamura; T Akiyama; K Ueno; I Miyazaki
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

7.  Liver Resection for Primary Intrahepatic Stones: Focus on Postoperative Infectious Complications.

Authors:  Gennaro Clemente; Agostino M De Rose; Rita Murri; Francesco Ardito; Gennaro Nuzzo; Felice Giuliante
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

8.  Hepatic resection for primary hepatolithiasis: a single-center Western experience.

Authors:  Parissa Tabrizian; Ghalib Jibara; Brian Shrager; Myron E Schwartz; Sasan Roayaie
Journal:  J Am Coll Surg       Date:  2012-08-24       Impact factor: 6.113

9.  Aspirin use and the risk of cholangiocarcinoma.

Authors:  Jonggi Choi; Hassan M Ghoz; Thoetchai Peeraphatdit; Esha Baichoo; Benyam D Addissie; William S Harmsen; Terry M Therneau; Janet E Olson; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Hepatology       Date:  2016-04-26       Impact factor: 17.425

10.  High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study.

Authors:  Jung Hyun Jo; Moon Jae Chung; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Kyung Sik Kim; Woo Jung Lee; Si Young Song; Jae Bock Chung
Journal:  Surg Endosc       Date:  2013-06-13       Impact factor: 4.584

View more
  8 in total

1.  Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones.

Authors:  Hyun Jung Kim; Tae Uk Kang; Heather Swan; Min Ji Kang; Nayoung Kim; Hyeong Sik Ahn; Seon Mee Park
Journal:  Dig Dis Sci       Date:  2018-08-31       Impact factor: 3.199

2.  Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system.

Authors:  Ze-Wu Meng; Wei Pan; Hai-Jie Hong; Jiang-Zhi Chen; Yan-Ling Chen
Journal:  Oncotarget       Date:  2017-09-15

3.  Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems.

Authors:  Ze-Wu Meng; Wei Pan; Hai-Jie Hong; Jiang-Zhi Chen; Yan-Ling Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Functional analysis of the correlation between ABCB11 gene mutation and primary intrahepatic stone.

Authors:  Lang Gan; Shuguang Pan; Jinchi Cui; Jie Bai; Peng Jiang; Yu He
Journal:  Mol Med Rep       Date:  2018-11-15       Impact factor: 2.952

5.  A novel prognostic model for diagnosing atypical bile duct hyperplasia in patients with intrahepatic lithiasis.

Authors:  Hongcheng Lu; Hao Yang; Linquan Wu; Wenjun Liao; Xianping He; Enliang Li; Rongshou Wu; Shidai Shi; Zhilong Yang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

6.  Preoperative prediction of intrahepatic cholangiocarcinoma lymph node metastasis by means of machine learning: a multicenter study in China.

Authors:  Tingfeng Huang; Hongzhi Liu; Zhaowang Lin; Jie Kong; Kongying Lin; Zhipeng Lin; Yifan Chen; Qizhu Lin; Weiping Zhou; Jingdong Li; Jiang-Tao Li; Yongyi Zeng
Journal:  BMC Cancer       Date:  2022-08-29       Impact factor: 4.638

7.  Modified percutaneous transhepatic papillary balloon dilation for patients with refractory hepatolithiasis.

Authors:  Bin Liu; Pi-Kun Cao; Yong-Zheng Wang; Wu-Jie Wang; Shi-Lin Tian; Yancu Hertzanu; Yu-Liang Li
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

8.  A Preliminary Study of Biliary Microbiota in Patients with Bile Duct Stones or Distal Cholangiocarcinoma.

Authors:  Bingrong Chen; Seng Wang Fu; Lungen Lu; Hang Zhao
Journal:  Biomed Res Int       Date:  2019-09-25       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.